SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Bio Medica Laboratories Ltd (BMLL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BMLL Pharmaceuticals & Drugs | Small Cap | Bio Medica Laborator Share Price

BSE Share Price
Not Listed

Bio Medica Laboratories Ltd (BMLL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BMLL Pharmaceuticals & Drugs | Small Cap | Bio Medica Laborator Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹147 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹7.8
TTM Sales
₹38.2 Cr.
Book Value per Share
₹14.4
P/E Ratio
14.98
Higher than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
8.10
Higher than its 5-year historical median
Price to Sales (P/S)
3.84
Higher than its 5-year historical median
EV/EBITDA
10.43
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
99.59%
Return on Capital Employed (ROCE)
64.18%
Return on Assets (ROA)
33.60%
Operating Profit Margin
40.2%
Net Profit Margin
25.64%
Gross Profit Margin
37%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
150.49%
Operating Profit Growth (1 Year)
-
173%
Net Profit Growth (1 Year)
-
291.6%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹6 Cr.
Equity
₹12.6 Cr.
Face Value
₹10
All Time Low / High
- / -

Bio Medica Laboratories stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bio Medica Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'23Mar'24Mar'25TTM
ROCE % ⓘ10.2%33.6%64.2%-
Value Creation
Index ⓘ		-0.31.43.6-

Growth Parameters ⓘ
Sales ⓘ16.215.338.238
Sales YoY Gr.--6%150.5%-
Adj EPS ⓘ0.42.710.77.8
YoY Gr.-655.6%292.3%-
BVPS (₹) ⓘ2.75.416.114.4
Adj Net
Profit ⓘ		0.32.59.810
Cash Flow from Ops. ⓘ2.31.6-3.7-
Debt/CF from Ops. ⓘ4.26.5-4.1-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANANA150.5%
Adj EPS ⓘNANANA292.3%
BVPSⓘNANANA198.3%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		13.767.799.651.1
Op. Profit
Mgn % ⓘ		10.536.940.3NAN
Net Profit
Mgn % ⓘ		2.116.425.625.7
Debt to
Equity ⓘ		3.92.11-
Working Cap
Days ⓘ		02382000
Cash Conv.
Cycle ⓘ		01031040

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales161538
Operating Expenses ⓘ + 151023
Manufacturing Costs8411
Material Costs5310
Employee Cost 111
Other Costs ⓘ 111
Operating Profit ⓘ 2615
Operating Profit Margin (%) 10.5%36.9%40.2%
Other Income ⓘ + 000
Exceptional Items ⓘ 000
Interest ⓘ 111
Depreciation ⓘ 011
Profit Before Tax ⓘ 0413
Tax ⓘ 013
Profit After Tax 0210
PAT Margin (%) 2.1%16.4%25.6%
Adjusted EPS (₹)0.42.710.7
Dividend Payout Ratio (%)0%0%0%

Valuation of Bio Medica Laborator - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2515
Share Capital ⓘ 009
Reserves ⓘ 256
Debt +8913
Long Term Debt587
Short Term Debt426
Minority Interest000
Trade Payables524
Others Liabilities ⓘ 237
Total Liabilities ⓘ 181939

Fixed Assets

Net Fixed Assets ⓘ +898
Gross Block101212
Accumulated Depreciation234
CWIP ⓘ 000
Investments ⓘ 000
Inventories4718
Trade Receivables424
Cash Equivalents 000
Others Assets ⓘ 119
Total Assets ⓘ 181939

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 22-4
PBT ⓘ 0413
Adjustment ⓘ 122
Changes in Working Capital ⓘ 1-4-18
Tax Paid ⓘ -0-0-1
Cash Flow From Investing Activity ⓘ + -2-20
Capex -2-20
Net Investments 000
Others ⓘ 0-00
Cash Flow From Financing Activity ⓘ + -2-03
Net Proceeds from Shares ⓘ 000
Net Proceeds from Borrowing ⓘ 13-1
Interest Paid ⓘ -1-1-1
Dividend Paid ⓘ 000
Others ⓘ -2-26
Net Cash Flow ⓘ -20-0

Financial Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)13.6767.7499.59
ROCE (%)10.1733.6164.18
Asset Turnover Ratio0.930.831.31
PAT to CFO Conversion(x)N/A1-0.4
Working Capital Days
Receivable Days91.6076.7030.80
Inventory Days87.80134.90121.90
Payable Days360.70361.40117.70

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bio Medica Laboratories Ltd FAQs

The current trading price of Bio Medica Laborator on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Bio Medica Laborator stood at ₹146.8 Cr

The latest P/E ratio of Bio Medica Laborator as of 31-Dec-1969 is 14.98.

The latest P/B ratio of Bio Medica Laborator as of 31-Dec-1969 is 8.10.

The 52-week high of Bio Medica Laborator is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bio Medica Laborator is ₹38.20 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bio Medica Laboratories Ltd is a below average quality company.

The key valuation ratios of Bio Medica Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bio Medica Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Bio Medica Laboratories Ltd

Bio Medica Laboratories was originally incorporated as a private limited company with the name of ‘Bio Medica Laboratories Private Limited’ under the Companies Act, 2013 vide certificate of incorporation dated August 14, 2015, issued by Registrar of Companies, Gwalior. Further, the company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of the Company at the Extra- Ordinary General Meeting held on September 09, 2024 & name of the company changed from ‘Bio Medica Laboratories Private Limited’ to ‘Bio Medica Laboratories Limited’ & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated October 24, 2024.

Bio Medica Laboratories is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The company operates on a B2B business model through contract manufacturing and does not deal directly with the end users. The company manufactures formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, it enters into agreements with them, allowing their name and address to be displayed on the packaging as ‘Technical Collaborator’ or ‘marketed by’ alongside the company’s name as the manufacturer.

The company holds Good Manufacturing Practices (GMP) certificate issued by Food & Drugs Administration, Madhya Pradesh, for complying with established GMP standards and guidelines. The company maintain stringent quality control standards throughout the entire manufacturing process. 

Business area of the company

Bio Medica Laboratories is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences.

Products of the company

Liquid injectables

  • 100ml Amikacin Sulphate IP injection
  • Vitamin B12, D3 & Calcium Gluconolactobionate injection
  • 2ml Amikacin Sulphate injection
  • Buprenorphine injection
  • 30ml Amikacin Sulphate injection

Dry Powder Injectables

  • Piperacillin & Tazobactam injection
  • Ceftrixone & Sulbactam for injection
  • Meropenem injection
  • Ceftriaxone injection
  • Artesunate injection

History and milestones

  • 2015: Incorporation of Company.
  • 2024: Alteration of Name clause of Memorandum of Association and subsequently Conversion of the Company from Private Limited Company into Public Limited Company.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×